Exa vs Recursion Pharmaceuticals
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Exa
Web search and retrieval API built for AI agents and apps
Visit
|
Recursion Pharmaceuticals
Publicly traded techbio company (NASDAQ: RXRX) industrialising drug di...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 7.7 / 10 | 7 / 10 |
| Capability | — | |
| Value for money | — | |
| Ease of use | — | |
| ASEAN readiness | — | |
| API quality | — | |
| Pricing | Freemium | Enterprise |
| Free tier | 20,000 search requests per month on the free plan; startup and education grants of $1,000 in free API credits also available | — |
| Paid from | API search billed at $7 per 1,000 requests (as of March 2026 pricing update) | Partnership / collaboration deals (not a self-serve product) |
| Has API | ✓ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✓ | ✗ |
| Users | — | — |
| Founded | 2021 | 2013 |
| Maker | — | Chris Gibson |
| Verdict | Exa earns its credibility through customer names, not just claims: Cursor, Notion AI, Cognition and OpenRouter all use it in production, and a $250M Series C at a $2.2B valuation (May 2026, led by a16z) backs that up. Th... |
What this is for: AI-driven, industrial-scale drug discovery combining large biological datasets, automated experiments and its own supercomputing. Who this is for: Pharmaceutical and biotech partners, plus investors in... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.